No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
OGN Organon & Co
- 18.830
- +0.220+1.18%
Close May 1 16:00 ET
- 18.800
- -0.030-0.16%
Post 18:36 ET
4.84BMarket Cap4.72P/E (TTM)
19.120High18.590Low2.40MVolume18.610Open18.610Pre Close45.09MTurnover0.94%Turnover Ratio4.72P/E (Static)257.17MShares22.85152wk High-69.23P/B4.83BFloat Cap10.67152wk Low1.12Dividend TTM256.40MShs Float35.537Historical High5.95%Div YieldTTM2.85%Amplitude10.671Historical Low18.802Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Organon & Is Maintained at Overweight by Piper Sandler
Organon & Is Maintained at Overweight by Piper Sandler
Organon & Price Target Raised to $24.00/Share From $22.00 by Piper Sandler
Organon & Price Target Raised to $24.00/Share From $22.00 by Piper Sandler
Piper Sandler Maintains Overweight on Organon, Raises Price Target to $24
Piper Sandler analyst David Amsellem maintains Organon (NYSE:OGN) with a Overweight and raises the price target from $22 to $24.
Organon Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/29/2024 29.38% Piper Sandler $22 → $24 Maintains Overweight 02/20/2024 -2.96% Goldman Sachs $16 → $18 M
Piper Sandler Reaffirms Their Buy Rating on Organon (OGN)
CVS Favors Humira Copycats Hurting AbbVie's Market Share: Evercore
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg